Skip to main content
. 2020 Jan 23;11(3):679–685. doi: 10.1111/1759-7714.13317

Figure 2.

Figure 2

Treatment response among HER2 mutated lung cancer patients as a whole. Treatment response was different between HER2‐targeted TKIs and chemotherapy, both in (a) first‐line and (b) second‐line settings.